The pharmaceutical landscape is rapidly changing as patents for some of the blockbuster drugs of the last decade near expiration and other players try to grab some of the remaining revenues before ge

Vivus (VVUS) is raising the bar on erectile dysfunction drugs, potentially becoming the latest formidable competitor to Viagra and Cialis in the $3.8 billion market. Investors in the California-based

Kids are more stressed out this year -- and many parents are missing or ignoring the signs.That appears to be the conclusion of the American Psychology Association's annual Stress in America survey,

For the tobacco industry, there’s a lot of money to be made by getting people hooked on cigarettes and keeping them as customers for life. But smoking cessation products are increasingly sendin

Seeing shades of blue? On November 14, the whole globe will be seeing them, too. The International Diabetes Federation (IDF) is hosting World Diabetes Day and asking that monuments around the globe b

Avian influenza (H5N1), sometimes known as bird flu, is a highly contagious animal disease caused by viruses that infect birds and, less commonly, pigs. On rare occasions it has crossed over to human

Dendreon (DNDN) has been one of the better-performing stocks in 2009, up over 500% on the strength of positive results from the IMPACT trial of Provenge for prostate cancer. As one of the

As consumer spending takes a hit and service-related companies continue to struggle, some sectors seem to continue to flourish -- namely, biotechnology. And for good reason. One major reason the sect

The global pharmaceuticals market is expected to reach $967 billion by 2011 -- which is why companies are always looking for that next must-have drug. Staying profitable and pleasing shareholders mea

The Thursday blur is ready to purr as we ready for our frisky fix. You know the drill by now. The market broke out about S&P 956, traded straight to near-term resistance at S&P 980 and slithe